T therapy programs for cancer therapy has resulted in improvements in remission induction rates as well as in disease-free survival. As most chemotherapeutic agents are not specifically cytotoxic for malignant cells, these advances have occurred in conjunction with substantial toxicity. The narrow therapeutic index displayed by chemotherapeutic drugs, the development of malignant cell resistance to these drugs, and the poor outcome of patients who relapse after intensive chemotherapy programs underscore the need for additional treatment modalities. The rational design and development of such modalities should emphasize agents that have novel mechanisms of action, address the systemic nature of these diseases, and are selective for the target tumor cell population. DAB4861L-2 is a genetically engineered cytotoxin that largely encompasses these characteristics.
DAB4861L-2 is a recombinant fusion toxin in which the native receptor binding domain of diphtheria toxin has been replaced with human interleukin-2 (IL-2). Because this substitution was accomplished at the level of the gene, this fusion toxin is expressed and purified from recombinant Escherichia coli. DAB4861L-2 has been shown to selectively bind and intoxicate only those cells that bear the high-affinity receptor for IL-2.1-3 Moreover, the cytotoxic action of DAB4861L-2 has been shown to be mediated through binding to the high-affinity IL-2 receptor (IL-2R), the induction of rapid receptor-mediated endocytosis, and the ADP-ribosylation of elongation factor-2 with resultant inhibition of protein synthesis in target
The high-affinity form of the IL-2R is an attractive target for cytotoxic cancer therapy. While this receptor is transiently expressed on the surface of activated T and B lymphocytes and recently activated macrophages, it is not found on other normal tissue^.^-^ In contrast, various hematologic malignancies, including Hodgkin's disease (HD), hairy cell leukemia, the lymphoid blast crisis of chronic myeloid leukemia (CML), and non-Hodgkin's lymphoma (NHL) have been shown to constitutively express the receptor for IL-2. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] In this report, we describe the first clinical trial of a a monophasic clearance of 5.8 f 0.7 minutes with peak levels of 3.549 f 1,041 mgImL at the 0.1 m g l k g dose. Approximately 50% of patients developed an antibody response t o diphtheria toxin or DABalL-2. The presence of such antibodies did not preclude patients from experiencing an antitumor response as four of the six patients with antitumor effect had detectable antibody titers. Although this was a phase I trial designed t o define the safety of DAB-IL-2, remissions were observed in three patients lasting from 5 t o over 18 months. The ability t o achieve significant tumor reductions in this group of heavily treated patients is encouraging and suggests additional trials are warranted in hematologic malignancies. 0 1992 by The American Society of Hematology.
genetically engineered ligand fusion toxin in patients with chemotherapy-resistant IL-2R expressing malignancies. While this study was designed to assess the safety, tolerability, single and multiple dose pharmacokinetics, and biologic effects of DABa61L-2, objective antitumor responses were observed.
MATERIALS AND METHODS

Description of DABM~ZL-2.
DAB4gIL-2 is a genetically engineered fusion protein isolated from the extracts of E coli by immunoaffinity chromatography and high performance liquid chromatography, as previously described.'~~ Briefly, the recombinant gene was created by replacing the diphtheria toxin receptor binding domain with a synthetic gene encoding IL-2 and a translational stop signal.' The purified chimeric toxin has been shown to selectively inhibit protein synthesis in high-affinity IL-2R-bearing target cells (IC50 5 To be eligible for entry, patients had to have a hematologic malignancy that could not be effectively treated with either standard or, in some cases other experimental therapy. Histologic mol/L; 68,000 ~~g l m L ) .~.~ confirmation of the malignancy was required, as was evidence of IL-2R (CD25) expression. Patients over the age of 17 years of either sex could be entered if they had an adequate hepatic and renal function and a performance status score of 70% or greater (Karnofsky). Patients were excluded if they had clinically significant retinopathy, serious active infection, central nervous system (CNS) involvement or history of seizure disorder, significant cardiac disease, or were pregnant. Patients could not have had treatment for their cancer for 3 weeks before study entry (6 weeks for experimental therapy).
The study was designed as a cohort dose escalation in single and multiple doses, beginning at 0.0007 mg/kg/d, which is 1.5% of the "no toxic effect" dose when administered for 14 daily doses in monkeys. DAB46IL-2 was administered as a daily intravenous bolus over 1 to 5 minutes. The first cohort received an initial dose, then 48 hours later, three daily doses, and 1 week later, seven daily doses (total 11 doses). Subsequent cohorts received three, and 1 week later seven, daily doses (total 10 doses). The 1-week interval between the three and seven daily doses allowed for examination of daily as well as cumulative toxicities. The three daily doses at a given level are similar to the seven daily doses of the previous level. Patients were entered successively at predetermined dose levels in groups of three to establish the maximal tolerated dose (MTD) ( Table 1) . Patients could receive an additional course a minimum of 4 weeks after the first day of therapy depending on tolerability and tumor response. Any patient could escalate to a higher dose level providing that a patient who had not previously received DAB486IL-2 completed evaluation at that level. Responding patients could enter a maintenance schedule consisting of seven daily infusions repeated every 21 to 28 days after the first dose. DABedL-2 administration was temporarily suspended for grade I11 toxicities and resumed at a 50% dose reduction once the toxicity resolved.
Patients had complete physical examinations, including relevant tumor measurements, before study entry and each course of therapy. Direct and indirect ophthalmoscopic examination, including tests for visual acuity, visual fields, color vision, and retinal photographs, was performed by a consulting ophthalmologist prestudy and poststudy. A brief physical examination was performed daily during DABe6IL-2 administration and twice per week thereafter. Laboratory parameters were monitored three times per week and included complete blood count with differential, serum chemistries, serum electrolytes, prothrombin time, partial thromboplastin time, and urinalysis.
At each dose level, patients were evaluated for safety and antitumor effects. Toxicities were scored according to the Common Toxicity Criteria established by the National Cancer Institute (NCI) for phase I trials. While the major thrust of this study was to establish the MTD, efforts were also made to evaluate efficacy. Evidence of response was based on clinical symptoms, malignant involvement of bone marrow and peripheral blood, bidimensional Patient assessment. Peripheral blood mononuclear cells were cultured in the presence of phytohemagglutinin (PHA) for up to 3 days. At 48 hours, cultures were pulsed with 3H-thymidine, harvested 16 to 20 hours later, and counted by liquid scintillation to determine thymidine incorporation. Responses were scored as follows: unresponsive,
cpm. Complement components and Ig levels were determined weekly, and delayed type hypersensitivity to seven recall antigens using the CMI-MULTITEST (Merieux Institute, Miami, FL) was performed before and after each course. Serum samples were obtained at 1-to 2-week intervals for assessment of the presence of antibodies to DAB486IL-2, diphtheria toxin, IL-2, and purification process residuals (horse IgG and E coli proteins) by enzyme-linked immunosorbent assay (ELISA).
For detection of anti-DABeIL2, diphtheria toxin, IL-2, horse IgG, or E coli protein antibodies in sera, 96-well flexible plates (Falcon MicroTest 111; Becton Dickinson, Oxnard, CA) were coated with 1 pg per well of the appropriate antigen in 50 pL of phosphate-buffered saline (PBS) and incubated at 4"C.21,22 After 16 hours, the plates were blocked for 1 hour with 100 FL per well of 0.1% gelatin prepared in 0.05% Tween 20 in PBS (PBS-Tween). Eight serial fivefold dilutions of each serum sample were added to the coated plate (100 pL per well) and incubated for 1 hour at room temperature. The plates were rinsed three times with PBS-Tween. One hundred microliters of protein A-alkaline phosphatase (Boehringer Mannheim Biochemicals, Indianapolis, IN) or goat antihuman IgG (for detection of antibodies to horse IgG; Cappel, Durham, NC) diluted in PBS-Tween was added to each well and incubated for 1 hour at room temperature. The plates were rinsed three times with PBS-Tween and two times with PBS. One hundred microliters of substrate (pNPP; Kirkegaard and Perry, Gaithersburg, MD) was added to each well and the plate was incubated for 10 minutes. The greatest dilution of serum that produced an absorbance greater than or equal to 0.1 on an automated plate reader was used as the end-point titer. Source of antigens: DAB4861L-2 (Seragen, Hopkinton, MA), diphtheria toxin (List Biological Laboratories, Campbell, CA), horse IgG (Connaught Laboratories, Inc, Swiftwater, PA), IL-2 (J. Murphy, Boston University Medical Center, Boston, MA), E coli protein (Seragen).
Samples were drawn for serum drug levels on the first day of dosing and the last day of the 7-day dosing schedule from patients who received doses of 0.05 mg/kg/d or higher. Time intervals for sampling were initially pretreatment, 0 (end of infusion), 1,5,10,15,30,45,60,75,120,180, and 240 minutes after the end of the bolus dose. As pharmacokinetic information became available, the timing of these determinations was substantially modified. To assay for DABa6IL-2, serum samples were diluted in RPMI 1640 (GIBCO, Grand Island, NY) containing 15% fetal calf For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From PHASE I TRIAL OF DABWJL-2 serum (FCS; Hazelton Biologics, Inc, Lenexa, Ks), and 2 mmol/L glutamine. One hundred microliters of each dilution was added to triplicate wells of a 96-well V-bottomed plate containing 105 C91/PL cellsU in 100 JLL of complete medium. The cells were incubated at 37°C for 18 hours in air containing 5% COz. The plates were then centrifuged at 17% for 5 minutes to pellet the cells. The medium was aspirated from each well and replaced with 100 pL of leucine-free medium (MEM; GIBCO) containing 5 pCi/mL L-[2,3,4,5-3H]-leucine (100 Ci/mmol; ICN, Irvine, CA). The cells were gently resuspended and incubated at 37°C. After 120 minutes, cells were harvested on glass fiber filters containing solid scintillant (Beckman Ready Filter, Fullerton, CA) and counted. Radioactive incorporation in cells treated with a reference lot of DAB4861L-2 was determined by a comparison of the sample activity to the specific activity of the particular lot of test material used in this study. Values for plasma concentrations of DAB486IL-2 at various times after bolus administration were subjected to nonlinear regression analysis for calculation of standard pharmacokinetic parameters (RSTRIP; Micromath, Inc, Salt Lake City, UT).
The presence of the IL-2R on malignant cells was evaluated by standard immunohistochemical analysis of frozen sections of tissue from involved lymph nodes or by flow cytometric analysis of cells from involved lymph nodes or bone marrow aspirates and peripheral blood. For both assays, an antibody to the p55 subunit of the IL-2R (CD25) (Becton Dickinson, Mountain View, CA) was used to detect the presence of the receptor on the surface of the cells bearing a marker for the malignant cell of interest.
Flow cytometric analysis of peripheral blood cells of various phenotypes was performed by the whole blood lysis technique as p u b l i~h e d .~~~~~ Specific monoclonal antibody (MoAb) combinations were used that provided information on the coexpression of CD25 and T (CD3, CD4, CD5, CD8), B (CD19, CD20), and natural killer (NK) (CD16, CD56) markers. All reagents were conjugated to either fluorescein or phycoerythrin (Becton Dickinson).
Soluble receptors for IL-2 (sIL-2R) were measured with an ELISA test kit (Cell Free; T-cell Sciences, Inc, Cambridge, MA), which is based on a modification of the method of Rubin et aLZ6 The potential interaction of sIL-2R with DAB4861L-2 was evaluated in vitro by assessing the cytotoxicity of DABa61L-2 in the presence or absence of IL-2R on the C91/PL cell lines as described above.
Detection ofthe IL-2R.
RESULTS
The characteristics of the 18 patients enrolled in this study are listed in Table 2 . Fourteen men and four women with a median age of 59 years and a median performance status of 90% were treated. Nine of the patients had NHL, three had HD, five had chronic lymphocytic leukemia (CLL), and one had cutaneous T-cell lymphoma (CTCL). The malignant cells from all NHL patients and three of four CLL patients expressed surface markers indicating they were of B-cell origin. All patients' tumors stained positively for the expression of the lowaffinity IL-2R (p55) by antibody staining. The patient with CTCL and one with CLL had tumors that expressed markers indicating a T-cell origin. The patients had been extensively treated before study entry, having received a median of 17 courses of treatment with a median of five different conventional and/or experimental therapies. DAB486IL-2 was well tolerated at all dose levels in this group of patients with advanced malignancies ( 3). Mild side effects of nausea and localized rash occurred in one patient each. Two patients with preexisting renal insufficiency from cis-platinum therapy developed grade I and grade 11, respectively, transient increases in serum creatinine. Three additional patients all with a previous history of intermittent proteinuria developed reversible proteinuria possibly related to DAB486IL-2. Three patients receiving the bolus infusion at the highest dose level developed chest tightness that did not recur when the infusion was prolonged to 10 minutes. Fever was sporadically observed in five patients, but either spontaneously resolved or readily responded to acetominaphen. No opportunistic infection occurred in patients treated with DABdX6IL-2. Two patients with CLL developed a bacterial pneumonia and sinusitis, respectively, and two additional patients developed urinary tract infections during the study period. None of these infections were thought to be drug related, because each patient had experienced similar infections before study and all infections responded readily to antibiotics. There were also no changes in lymphocyte phenotype in nonleukemic patients, nor were there changes in lymphocyte blastogenesis assays. Cells from leukemic patients were unresponsive to stimulation by mitogen.
Samples from patients treated at or above the 0.05 mg/kg/d dose levels were analyzed to determine single-and multiple-dose pharmacokinetic parameters. Complete data are available from eight treatment cycles administered to five patients. Pharmacokinetic data obtained from additional patients is incomplete due to patient refusal or inadequate specimens. Serum concentrations of DAB4861L-2 were measured by bioassay as described in Materials and Methods. Data analysis of the serum concentrations using nonlinear regression showed that the clearance of the drug closely fit a one-compartment open mathematical model (Fig 1) . The serum half-life of DAB4861L-2 was approximately 5 minutes at both the 0.05 and the 0.1 mg/kg dose levels ( Table 4, Fig 1) . The immediate apparent volume of distribution (Vd) was 6.3 f 1.0 L at the 0.05 mg/kg level and decreased slightly to 3.9 f 1.0 L at the 0.1 mg/kg dose. In contrast to the clearance and Vd, which did not vary substantially with dose, the area under the concentration curve ( e t ) increased nearly fourfold with an increase of daily dose from 0.05 to 0.1 mg/kg (Table 4 ). This divergence can be ascribed to a fourfold increase in the concentration of DAB4861L-2 at the end of the 0.1 mg/kg bolus administration, which may reflect saturation of immediate clearance sites at the higher dose of agent (Table 4, Fig 1) . The pharmacokinetics of multiple- dose administration in patients at different dose levels were not altered in a consistent fashion, suggesting that DAB4s61L-2 does not induce cumulative changes in its own clearance when administered as an intravenous bolus. Increases in hepatic transaminases, which occurred in some patients treated at dose levels above 0.05 mg/kg/d, were associated with peak levels above 600 ng/mL and Cxt greater than 5,000 ng/mL/min.
The sIL-2R is a cleavage product of the low affinity (p55) subunit of the IL-2R complex.26 This 40-Kd fragment has been shown to be elevated in a number of m a l i g n a n~i e s~~-~~ and may be a marker for tumor burden. All patients within this trial had elevated sIL-2R levels at the beginning of the trial with a median value of 8,016 U/mL (range, 1,046 to 11,346; normal, <500 U/mL). The presence of sIL-2R did not necessarily prevent antitumor activity, as all responding patients had elevated levels. This is consistent with the observation that the presence of sIL-2R up to 50,000 U/mL did not inhibit the cytotoxic action of DAB4861L-2 in vitro (Fig 2) . Additionally, sIL-2R did not change with administration of individual doses of DAB4x61L-2, but did decline in three patients in association with antitumor response (Table 5) .
Before receiving DAB4s61L-2, four patients had detectable antidiphtheria toxin antibodies, and two patients had detectable anti-DAB4861L-2 antibodies sIL-2R. ( Table 6 ). Nine of the 18 patients were found to have antibody to both diphtheria toxin and DAB4861L-2 by the end of the study period. Three patients entered the study with detectable antibody titers to IL-2 and two additional patients acquired anti-IL-2 antibodies after one course coincident with antidiphtheria toxin and anti-DAE34861L-2 antibodies.
Antibody status.
The presence of antidiphtheria toxin antibodies might be expected to influence clearance. We had the opportunity to examine this question in a single patient (12) who achieved a PR after receiving three courses of DABa61L-2. After the first dose of the fourth course, the patient received intravenous Ig (Sandoglobulin; Sandoz Corp, Hanover, NJ) Containing antidiphtheria toxin antibodies. The patient had no detectable antidiphtheria toxin antibodies before the administration of the Ig, but had a titer of 1:25 afterward. Clearance of DAB4*,IL-2 on day 1 (without antibodies), and day 2 (with antibodies) is depicted in Fig 3. In contrast to what might have been predicted, the peak serum level was higher and the clearance was not enhanced when DAB4861L-2 was administered in the presence of antibodies. Most importantly, the administration of antidiphtheria toxin antibody had no effect on the toxicity profile or pattern of response. This experience in a single patient was further supported by the observation that two patients achieved a PR in the presence of antibodies to diphtheria toxin and DAB4861L-2 (Table 5 ). Immune system status. No detectable effects on immune function were observed and no significant changes in complement levels or quantitative Igs were noted. As the majority of patients were anergic to a recall antigen panel (CMI-MULTITEST) before therapy, the test was discontinued after 10 patients were enrolled. Of seven patients retested for delayed type hypersensitivity (DTH) response posttreatment, one developed a DTH response to diphtheria antigen. Another patient remained reactive to old tuberculin on retesting, with the remainder of those tested being anergic.
Rank (titer)
Of the 12 nonleukemic patients studied for lymphocyte blastogenesis, five were unresponsive while seven responded within the established normal range. Furthermore, treatment did not significantly alter these responses. All leukemic patients were unresponsive to mitogenic stimulation before, during and after treatment. Nevertheless, normal T-cell activation remained intact because T-lymphoblasts from all patients retained their ability to ' *"*R. For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From express surface IL-2R after stimulation with PHA. These data suggest that treatment with DAB4861L-2 did not impair normal immune function.
Flow cytometric analysis of peripheral blood mononuclear cells was available for all patients. Ten of the 12 nonleukemic patients had no significant changes in the percentage or absolute numbers of lymphocytes in the peripheral circulation. The remaining nonleukemic patients (5 and 7) experienced a lymphocytosis in conjunction with DAB4861L-2 administration characterized by a specific increase in the percent and absolute number of cells that coexpress CD4 and CD25. There was a concomitant decrease in the percent of CD8 expressing cells in these patients, resulting in an increase in the CD4/CD8 ratio. No changes in circulating cells expressing CD16 or CD56 were observed.
Objective major clinical response was observed in three patients ( Table 5) . A patient with a follicular large cell lymphoma of low tumor burden had complete resolution of his disease and has remained in an unmaintained CR for over 18 months. A patient with CLL and one with follicular small cell lymphoma each developed a partial remission lasting 5 months and continuing at 12 months, respectively. One additional patient with a B-cell NHL tumor had a minor response lasting 6 months. Antitumor effects were observed in at least one patient treated at each dose level. The heterogeneous patient group, varied dose levels, and other described limitations inherent in this phase I trial preclude any correlations of tumor responses with histology, dose level, tumor expression of IL-2R, sIL-~R, or anti-diptheria toxin antibodies.
Antitumor effects.
DISCUSSION
This report describes the first clinical study of a genetically engineered ligand fusion-toxin. In patients with IL-2R expressing hematologic malignancies, DAB4861L-2 is well tolerated when administered as an intravenous bolus and some patients with advanced, heavily treated IL-2R expressing malignancies experienced significant reduction in tumor size after therapy. These observations underscore the feasibility of using recombinant DNA methodologies to design rational biologic therapies for the treatment of cancer.
A diverse group of patients was entered into this phase I study (Table 2) . Despite the median age of 59 years, reflecting an older group of patients, DAB4861L-2 was well tolerated. The study group had received an average of five different therapies before study entry, with patients often unable to receive additional treatment due to compromised bone marrow or other organ function.
The patients entered on this study were required to have hematologic malignancies that expressed the IL-2R as shown by immunostaining with an antibody directed to the p55 subunit of the IL-2R. The p55 subunit, or low-affinity IL-2R, is only part of the high-affinity receptor c o m p l e~.~~-~~ Native IL-2 binds and is rapidly internalized by either the high-affinity (p55 and p75) or the intermediate-affinity (p75) form of the IL-2R.40,41 In contrast, at the pharmacologic concentrations achieved in this study, DAB4861L-2 selectively binds only to the high-affinity receptor complex and the kinetics of internalization are similar to that of native IL-2.3 While detection of p55 by antibody binding does not insure the presence or function of the high-affinity IL-2R, more definitive techniques such as IL-2 cross-linking or Scatchard analysis are cumbersome and not suitable for a clinical trial. Detection of p55 by immunostaining can also be technically difficult because of the requirement of a minimum receptor density. Additionally, tumor infiltrates of nonmalignant cells such as tumor-infiltrating lymphocytes may express IL-2R, further complicating the identification of IL3R on tumor cell populations. These technical difficulties, as well as the dose-finding nature of this study, may account for the inability to demonstrate a relationship between the level of IL-2R expression as measured in this trial and tumor response. The development of better techniques for the detection of the high-affinity IL-2R will be required to determine if the antitumor activity of DAB4861L-2 can be predicted. DAB4861L-2 administration was well tolerated at all dose levels and patients could receive multiple courses of therapy without difficulty, even in the presence of anti-DAB4861L-2 antibodies (Tables 3 and 6 ). The MTD in this study was established by asymptomatic, reversible elevations of hepatic transaminase without changes in other tests of liver function (Table 3 ). This observation is in keeping with drug localization studies performed in the rat that suggest that the liver is the major site of uptake and clearance of DAB4861L-2.42 The hepatic changes were not cumulative and did not prevent retreatment of patients on schedule. Two patients with documented renal insufficiency before study entry experienced transient elevations in serum creatinine. In both cases these elevations were mild, asymptomatic, and reversible. Several patients had fever that typically began 4 to 6 hours after the infusion and was easily controlled with acetaminophen. Two patients developed symptoms of chest tightness, but these did not recur when the duration of subsequent infusions was lengthened. The capillary-leak syndrome reported with immunoconjugates formed by linking ricin A-chain to murine MoAbs was not observed.
When administered by bolus infusion, DAB486IL-2 has a relatively short monophasic half-life of about 5 minutes ( Table 4 , Fig 1) . The minimum contact time required for killing target cells in vitro is about 15 to 30 minutes, a finding that is compatible with the observed antitumor activity.42 There was an increase in peak drug levels and a fourfold increase in area under the concentration curve in patients with elevations of hepatic transaminase at the highest dose (0.1 mg/kg/d). The brief half-life and the presence of higher serum levels in those patients with elevated liver function tests suggest that future trials should investigate longer infusion schedules to potentially further widen the therapeutic index. The presence of antidiphtheria toxin antibodies can also influence the pharmacology of DABdS6IL-2, but does not necessarily enhance clearance or compromise antitumor activitf2 (Fig 2; Table 5 ).
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The immune evaluation of these heavily treated patients before study confirmed deficiencies in immune function attributable to disease and prior therapy. No effects of DAB4861L-2 on the immune system were observed, although two patients with leukemia developed a lymphocytosis in conjunction with DAB4*JL-2 administration. The etiology and significance of this observation are not understood.
Approximately 50% of patients developed an antibody response to diphtheria toxin or DAB4861L-2 (Table 6 ). Antibody responses also appeared to be "blunted" because antibody titers tended to remain stable with repeated administration in contrast to the continued increases seen with repeated administration of murine MoAb immunoconjug ate^.^^ Some patients with antibodies directed toward diphtheria toxin or DAB4861L-2 experienced fever, chills, rash, and/or chest tightness, but no patient discontinued treatment because of these symptoms. The presence of such antibodies did not preclude patients from experiencing an antitumor response, as four of the six patients with antitumor effect had detectable antibody titers (Table 5 ). This observation is not surprising, as antibodies directed to epitopes of diphtheria toxin that are distinct from the binding region do not neutralize toxicity either in vitro or in vivo.22 Low titers of antibodies directed against IL-2 were detected in two patients before receiving DAB4861L-2 and in two additional patients after treatment. There were no identifiable side-effects associated with the presence of anti-IL-2 antibodies, so the significance of this finding remains unclear.
Although this was a phase I trial designed to examine the safety of DAB4&IL-2 and to establish possible doses for phase I1 investigation, antitumor activity was observed ( Table 5 ). The ability to achieve significant tumor reductions in this group of heavily treated patients is encouragicg and suggests that formal phase I1 trials are warranted in hematologic malignancies. The novel mechanism of cytotoxicity of DAB4@IL-2 and the favorable toxicity profile relative to the action of chemotherapeutic agents support continued development in patients with hematologic malignancies resistant to standard therapies. Questions to be addressed in these trials include further investigation of the relationship of the effect of DAB4%lL-2 administration schedule and of IL-2R expression to tumor response.
